Arthritis Society Canada supports Ontario’s transition to biosimilars
Arthritis Society Canada supports the Ontario government’s announcement made earlier today: Ontario Expanding Safe Use of Biosimilars. The announcement makes Ontario the eighth jurisdiction in Canada to transition patients to biosimilars medications.
“Arthritis Society Canada believes a switch to a biosimilar can take place safely under the right conditions, can improve access to treatment and provide savings to the health-care system. We look forward to working with the Ontario government to ensure the transition is seamless for patients and their families. Arthritis Society Canada has educational and support materials available to help patients and families learn more about biosimilars,” said Dr. Siân Bevan, Chief Science Officer.
Arthritis Society Canada’s priority is to ensure that people with arthritis have access to the life-changing treatments and information they need to fight the fire of Canada’s most common chronic condition.
Learn more by reading Arthritis Society Canada’s position on biosimilars and our resources on biologics and biosimilars.
About Arthritis Society Canada
Arthritis Society Canada is Canada’s national health charity, fueled by donors and volunteers, with a mission to fight the fire of arthritis with the fire of research, advocacy, innovation, information and support. Arthritis Society Canada is accredited under Imagine Canada’s Standards Program. For more information, visit arthritis.ca.
For more information or to arrange interviews:
Vice President, Marketing and Communications
Back to News
Directrice du marketing et des communications